OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Hartwich on Preclinical Findings for Y3 Plus Chemotherapy in Ovarian Cancer

May 1st 2024

Yang Yang Hartwich, PhD discusses a study delving into the mechanisms underlying chemoresistance in ovarian cancer.

Dr Ahluwalia on Advancements in the Management of Brain Metastases

April 30th 2024

Manmeet Singh Ahluwalia, MD, MBA, FASCO, discusses how advancements in precision medicine have improved outcomes for patients with brain metastases.

Dr Diaz on the Evolution of Precision Medicine in Cervical Cancer

April 30th 2024

John Paul Diaz, MD, discusses the evolving use of precision medicine approaches in cervical cancer management.

Dr Kopetz on the Future Utility of Adagrasib/Cetuximab in KRAS G12C–Mutant CRC

April 30th 2024

Scott Kopetz, MD, PhD, FACP, discusses the potential FDA approval of adagrasib in combination with cetuximab in KRAS G12C-mutatated colorectal cancer.

Dr Konecny on PROs From the MIRASOL Trial in Advanced Ovarian Cancer

April 30th 2024

Gottfried Konecny, MD, discusses the importance of evaluating PROs in patients with platinum-resistant ovarian cancer receiving mirvetuximab soravtansine.

Dr Jain on the VERONA Study in Higher-Risk MDS

April 30th 2024

Akriti Jain, MD, discusses the phase 1b VERONA study of venetoclax plus azacitidine in higher-risk myelodysplastic syndromes.

Dr Aldoss on the Mechanism of Action of Ponatinib in Ph+ ALL

April 29th 2024

Ibrahim Aldoss, MD, discusses the use of ponatinib as evaluated in the PhALLCON trial for patients with Ph+ ALL.

Dr Nanda on HER2-Low Status Testing in Early-Stage Breast Cancer

April 29th 2024

Rita Nanda, MD, discusses the importance of testing for HER2-low status in patients with early-stage breast cancer.

Dr Anderson on the FDA ODAC Decision Regarding Cilta-Cel in R/R Multiple Myeloma

April 29th 2024

Kenneth C. Anderson, MD, discusses the recent FDA ODAC decision regarding the use of cilta-cel in relapsed/refractory multiple myeloma.

Dr Fujiwara on the FDA Approval of Tisotumab Vedotin for Recurrent Cervical Cancer

April 29th 2024

Keiichi Fujiwara, MD, PhD, discusses the significance of the FDA approval of tisotumab vedotin for patients with recurrent or metastatic cervical cancer.

Dr Gopal on Future Research Directions in Non-ccRCC

April 26th 2024

Nikhil A. Gopal, MD, discusses future research directions for the treatment of various renal cell carcinoma histologies.

Dr Maxwell on Strategies to Optimize Genetic Testing in Metastatic Prostate Cancer

April 26th 2024

Kara N. Maxwell, MD, PhD, discusses strategies to optimize the utility of genetic testing to better inform decision-making in prostate cancer treatment.

Dr Kopetz on the Background of the KRYSTAL-1 Trial in KRAS G12C+ mCRC

April 26th 2024

Scott Kopetz, MD, PhD, FACP, discusses using adagrasib plus cetuximab in patients with metastatic colorectal cancer harboring KRAS G12C mutations.

Dr Nanda on the Evolution of CDK4/6 Inhibitor Treatment in HR+/HER2– Breast Cancer

April 26th 2024

Rita Nanda, MD, discusses the evolution of treatment with CDK4/6 inhibitors in patients with hormone receptor-positive/HER2-negative breast cancer.

Dr Fedorov on the Use of Quizartinib vs Midostaurin in FLT3+ AML

April 26th 2024

Kateryna Fedorov, MD, discusses considerations when deciding between quizartinib and midostaurin for patients with FLT3-mutated AML.

Dr Nye on Future Treatment Directions in HER2+ Breast Cancer Brain Metastases

April 26th 2024

Lauren E. Nye, MD, discusses future directions for the treatment of patients with HER2-positive breast cancer with brain metastases.

Dr Jurcic on the Use of JAK Inhibitors in Myelofibrosis Management

April 26th 2024

Joseph G. Jurcic, MD, discusses the use of JAK inhibitors in the management of myelofibrosis.

Dr Eroglu on Future Steps for Assessing Ceritinib Plus Trametinib in Metastatic Melanoma

April 26th 2024

Zeynep Eroglu, MD, discusses future steps for assessing ceritinib in combination with trametinib in patients with metastatic melanoma.

Dr Pantin on the Evolving Treatment Paradigm in PNH

April 25th 2024

Jeremy M. Pantin, MD, discusses the evolution of the PNH treatment paradigm and agents that are available or being investigated in this disease.

Dr Hafez on the Design of the FeDeriCa Trial in HER2+ Early Breast Cancer

April 25th 2024

Maria Hafez, MD, discusses the design of, and outcomes from, the phase 3 FeDeriCa trial in patients with HER2-positive early breast cancer.